Parvus Therapeutics Inc. has announced the achievement of a milestone under its collaboration with Abbvie Inc. to develop treatments for inflammatory bowel disease (IBD). PVT-401, a novel peptide-major histocompatibility complex (pMHC) nanomedicine (Navacim) drug candidate, has met prospective nonclinical pharmacology and manufacturing criteria.
Parvus Therapeutics Inc.'s PVT-201 has received orphan drug status from the U.S. FDA for the treatment of primary biliary cholangitis (PBC), an autoimmune disease of the liver.
Parvus Therapeutics Inc. has entered into an exclusive worldwide collaboration and option agreement with Abbvie Inc. for the development and commercialization of novel treatments for inflammatory bowel disease (IBD), utilizing Parvus’ Navacim regulatory T-cell (Treg) immune tolerization platform technology.
Parvus Therapeutics has announced an agreement with National Resilience for the tech transfer, scale-up and GMP manufacturing of PVT-201, Parvus' lead Navacim drug candidate being developed to treat primary biliary cholangitis.
